The company has four drug programs in clinical development and in preclinical and discovery stages.
Its three clinical programs are ACP-103 for treatment-induced dysfunctions in Parkinsonís disease, which is in phase II clinical trails; and ACP-103 and ACP-104, for the treatment of schizophrenia.
In addition, the company has neuropathic pain program in Phase I clinical trials and a glaucoma program in preclinical development in collaboration with Allergan, Inc.
ACADIA Pharmaceuticals was founded by Mark R.
The company was incorporated as Receptor Technologies, Inc.
in 1993 and is headquartered in San Diego, California.